查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402607

血管收縮素轉化酵素（ACE）抑制劑市場：依藥物、適應症、給藥途徑、分銷管道、地區

Angiotensin Converting Enzymes Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

血管收縮素轉化酵素（ACE）抑制劑的全球市場規模預計將從2023年的80.705億美元增加至2030年的118.317億美元，2023-2030年預測期間複合年成長率為5.6%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 80.705 億美元
實際資料 2018-2021 預測期 2023-2030
預測期複合年成長率 5.60% 2030年市場規模預測 118.317 億美元
圖 1. 2023 年依地區分類的血管收縮素轉化酵素(ACE) 抑制劑的全球市場佔有率(%)
血管緊張素轉換酶抑制劑市場-IMG1

血管收縮素轉化酵素（ACE）抑制劑是一類主要用於治療高血壓和心臟衰竭的藥物。它透過抑制血管收縮素II 激素的作用發揮作用。血管收縮素II 會收縮血管並刺激另一種稱為醛固酮的荷爾蒙的分泌，促使體內水分和鹽分儲存。 ACE抑制劑阻斷血管收縮素II的產生，血管緊張素II可以放鬆和擴張血管，減少體內保留的水量，並降低血壓。常用的 ACE 抑制劑包括賴諾普利、Enalapril和雷米普利。副作用包括乾咳、頭暈和腎臟損傷。對於服用 ACE 抑制劑的人來說，定期檢查以監測腎功能和鉀水平非常重要。 ACE 抑制劑透過調節血管收縮素II 的作用並幫助血管放鬆和擴張，同時調節液體儲存，發揮至關重要的作用，從而顯著降低血壓。

市場動態

全球血管收縮素轉化酵素（ACE）抑制劑市場的成長是由全球高血壓和心臟病的高盛行率所推動的。身體產生四種激素，稱為血管收縮素（an-gee-oh-ten-sin，類型名稱為羅馬數字）。血管收縮素I經由ACE轉化為血管收縮素II，具有多種物理作用。通常建議使用 ACE 抑制劑，特別是對於心血管疾病和高血壓。 2019 年，超過 1,290 萬名 Medicare D 部分用戶（約佔所有 D 部分受益人的 27%）接受了 ACE 抑制劑。 ACE抑制劑確實會引起不良反應。大多數是輕微的，但少數是危險的，需要緊急醫療護理。

本研究的主要特點

  • 本報告對全球血管收縮素轉化酵素（ACE）抑制劑市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。 。
  • 本報告還闡明了各個區隔市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
  • 本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 根據公司亮點、產品系列、主要亮點、業績和策略等參數，對全球血管收縮素轉化酵素(ACE) 抑制劑市場的主要參與者進行了分析。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
  • 全球血管收縮素轉化酵素(ACE) 抑制劑市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 相關人員可以透過分析全球血管收縮素轉化酵素(ACE) 抑制劑市場時使用的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
    • 促進因素
  • 高血壓盛行率上升
  • 不斷成長的研發活動
  • 提高心血管健康意識
    • 抑制因素
  • 專利到期日
  • 副作用和安全問題
  • 副作用和安全問題
    • 機會
  • 提高心血管健康意識
  • 個人化醫療
  • 聯合治療
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章全球血管收縮素轉化酵素(ACE) 抑制劑市場 –冠狀病毒(COVID-19) 大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章全球血管收縮素轉化酵素（ACE）抑制劑市場（依藥物），2018-2030

  • 貝那普利
  • 培哚普利
  • 川福普利
  • Captopril
  • Enalapril
  • 賴諾普利
  • 其他（雷米普利等）

第6章 2018-2030 年全球血管收縮素轉化酵素(ACE) 抑制劑市場（依適應症）

  • 高血壓
  • 冠狀動脈疾病
  • 心臟衰竭
  • 慢性腎臟病
  • 硬皮症
  • 其他（偏頭​​痛等）

第 7 章全球血管收縮素轉化酵素(ACE) 抑制劑市場，依給藥途徑，2018-2030 年

  • 口服
  • 可注射的

第8章2018-2030年全球血管收縮素轉化酵素（ACE）抑制劑市場（依通路）

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章2018-2030年全球血管收縮素轉化酵素（ACE）抑制劑市場（依地區）

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東和非洲
  • GCC
  • 以色列
  • 北非
  • 中部非洲
  • 其他中東和非洲

第10章競爭形勢

  • Novartis AG
  • Pfizer Inc.
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy's Laboratories Ltd.
  • Mylan

第11章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI2746

The global angiotensin converting enzymes (ACE) inhibitors market size is projected to reach US$ 11,831.7 million by 2030, from US$ 8,070.5 million in 2023, at a CAGR of 5.6% during the forecast period 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 8,070.5 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.60% 2030 Value Projection: US$ 11,831.7 Mn
Figure 1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Share (%), By Region, 2023
Angiotensin Converting Enzymes Inhibitors Market - IMG1

Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.

Market Dynamics

The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.

Key features of the study:

  • This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market

Detailed Segmentation:

  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
    • Benazepril
    • Perindopril
    • Trandfolapril
    • Captopril
    • Enalapril
    • Lisinopril
    • Others (Ramipril, etc.)
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication:
    • Hypertension
    • Coronary Artery Disease
    • Heart Failure
    • Chronic Kidney Disease
    • Scleroderma
    • Others (Migraine, etc.)
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration:
    • Oral
    • Injectable
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East &Africa
  • Company Profiles:
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co.
    • AstraZeneca
    • Sanofi
    • Boehringer Ingelheim
    • GlaxoSmithKline
    • Lupin Limited
    • Torrent Pharmaceuticals Ltd.
    • Reddy's Laboratories Ltd.
    • Mylan
    • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
    • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Rising prevalence of hypertension
  • Growing Research and Development Activities
  • Increasing Awareness of Cardiovascular Health
    • Restraints
  • Patent Expirations
  • Side Effects and Safety Concerns
  • Side Effects and Safety Concerns
    • Opportunities
  • Increasing Awareness of Cardiovascular Health
  • Personalized medicine
  • Combination therapies
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Benazepril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Perindopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Trandfolapril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Captopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Enalapril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Lisinopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others (Ramipril, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hypertension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Coronary Artery Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Heart Failure
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Chronic Kidney Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
  • Scleroderma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others (Migraine, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

9. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
  • GCC
  • Israel
  • North Africa
  • Central Africa
  • Rest of Middle East & Africa

10. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy's Laboratories Ltd.
  • Mylan
  • Analyst Views

11. Section

  • Research Methodology
  • About us